Based on this result, the global, randomized, phase 3 REACH-2 study (N = 292) was conducted in patients with HCC previously treated with sorafenib who had a baseline AFP level ≥ 400 ng/mL [20]. Here, AFP is linked to hepatocellular carcinoma.